Comparison of Cystatin-C Based eGFR and Creatinine Based eGFR to Assess Kidney Function in Patients With Chronic Kidney Disease Stage V Undergoing Hemodialysis at RSUD Dr. Mohamad Soewandhie Surabaya

Denny Chandra; Rahajoe Imam Santoso; Mulyadi Mulyadi

doi:10.55606/ijhs.v6i1.6881

Authors

Denny Chandra Universitas Ciputra
Rahajoe Imam Santoso Universitas Ciputra
Mulyadi Mulyadi Universitas Ciputra

DOI:

https://doi.org/10.55606/ijhs.v6i1.6881

Keywords:

Creatinine, Cystatin-C, Chronic Kidney Disease, Cross-Sectional Study, eGFR

Abstract

Chronic kidney disease (CKD) is a global health problem with continuously increasing incidence and mortality, and accurate assessment of kidney function is essential for disease staging and clinical decision making. Estimation of glomerular filtration rate (eGFR) based on serum creatinine using the CKD-EPI 2009 equation is widely used, however it is influenced by nonrenal factors such as age, sex, and muscle mass, whereas cystatin C is considered a more stable biomarker. This observational analytic study with a cross sectional design aimed to analyze the differences and agreement between creatinine based eGFR and cystatin C based eGFR in 53 patients with stage V CKD undergoing hemodialysis at RSUD dr. Mohamad Soewandhie Surabaya prior to dialysis. Creatinine based eGFR was calculated using the CKD-EPI 2009 equation and cystatin C based eGFR using the CKD-EPI 2012 equation. Statistical analysis was performed using the Wilcoxon signed rank test and Bland Altman analysis. The Wilcoxon test showed that all paired data had positive ranks with a Z value of –6.336 and p < 0.001, indicating a statistically significant difference. Bland Altman analysis demonstrated a bias of –41.64 mL/min/1.73 m² with limits of agreement ranging from –105.14 to 21.86, indicating that the two methods are not interchangeable. In conclusion, a significant difference exists between creatinine based eGFR and cystatin C based eGFR, and these methods cannot be used interchangeably in clinical practice among patients with stage V CKD at RSUD dr. Mohamad Soewandhie Surabaya.

Downloads

Download data is not yet available.

References

Andreoli, M. C. C., & Totoli, C. (2020). Peritoneal dialysis. Revista da Associacao Medica Brasileira, 66(Suppl 1), 37–44. https://doi.org/10.1590/1806-9282.66.S1.37

Barrett, K. E., et al. (2019). Ganong's review of medical physiology (26th ed.). McGraw-Hill Education.

Basher, H., et al. (2018). Serum cystatin C and creatinine level among chronic kidney disease patients undergoing hemodialysis. Scholars International Journal of Biochemistry.

Benoit, S. W., Ciccia, E. A., & Devarajan, P. (2020). Cystatin C as a biomarker of chronic kidney disease: Latest developments. Expert Review of Molecular Diagnostics, 20(10), 1019–1026. https://doi.org/10.1080/14737159.2020.1768849

Berns, J. S. (2015). Clinical decision making in a patient with stage 5 CKD-Is eGFR good enough? Clinical Journal of the American Society of Nephrology, 10(11), 2065–2072. https://doi.org/10.2215/CJN.00340115

Brunetti, L., et al. (2021). Evaluation and enhancement of standard equations for renal function estimation in individuals with components of metabolic disease. BMC Nephrology, 22(1). https://doi.org/10.1186/s12882-021-02588-4

Burballa, C., et al. (2018). MDRD o CKD-EPI en la estimación del filtrado glomerular del donante renal vivo. Nefrología, 38(2), 220–221. https://doi.org/10.1016/j.nefro.2017.02.007

Carrero, J. J., et al. (2023). Discordances between creatinine- and cystatin C-based estimated GFR and adverse clinical outcomes. American Journal of Kidney Diseases, 82(5), 534–542. https://doi.org/10.1053/j.ajkd.2023.04.002

Chen, D. C., et al. (2022). Association of intraindividual difference in estimated GFR by creatinine vs cystatin C with ESKD and mortality. JAMA Network Open, 5(2). https://doi.org/10.1001/jamanetworkopen.2021.48940

Cusumano, A. M., Tzanno-Martins, C., & Rosa-Diez, G. J. (2021). The glomerular filtration rate: From diagnosis to a public health tool. Frontiers in Medicine, 8, 769335. https://doi.org/10.3389/fmed.2021.769335

Delgado, C., et al. (2022). A unifying approach for GFR estimation: NKF-ASN task force recommendations. American Journal of Kidney Diseases, 79(2), 268–288.e1. https://doi.org/10.1053/j.ajkd.2021.08.003

Floris, M., et al. (2021). Chronic kidney disease of undetermined etiology around the world. Kidney and Blood Pressure Research, 46(2), 142–151. https://doi.org/10.1159/000513014

GBD Chronic Kidney Disease Collaboration. (2020). Global burden of chronic kidney disease, 1990-2017. The Lancet, 395(10225), 709–733. https://doi.org/10.1016/S0140-6736(20)30045-3

Geißer, D., et al. (2023). Questionable validity of creatinine-based eGFR in elderly patients but cystatin C is helpful. Geriatrics, 8(6), 120. https://doi.org/10.3390/geriatrics8060120

Gusev, E., et al. (2021). Pathogenesis of end-stage renal disease from inflammation theory. International Journal of Molecular Sciences, 22(21), 11453. https://doi.org/10.3390/ijms222111453

Huang, S. H. S., et al. (2015). The kinetics of cystatin C removal by hemodialysis. American Journal of Kidney Diseases, 65(1), 174–175. https://doi.org/10.1053/j.ajkd.2014.08.010

Inker, L. A., & Titan, S. (2021). Measurement and estimation of GFR for clinical practice. American Journal of Kidney Diseases, 78(5), 736–749. https://doi.org/10.1053/j.ajkd.2021.04.016

Indonesian Renal Registry. (2020). 3rd annual report of Indonesian Renal Registry 2020.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for CKD. Kidney International, 105(4), S117–S314. https://doi.org/10.1016/S0085-2538(24)00110-8

Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: An update. Kidney International Supplements, 12(1), 7–11. https://doi.org/10.1016/j.kisu.2021.11.003

Lee, H. S., et al. (2014). Comparison of cystatin C-based GFR equations in CKD patients. Kidney Research and Clinical Practice, 33(1), 45–51. https://doi.org/10.1016/j.krcp.2013.11.001

Levey, A. S., et al. (2020). Measured and estimated GFR: Current status and future directions. Nature Reviews Nephrology, 16(1), 51–64. https://doi.org/10.1038/s41581-019-0191-y

Pottel, H., Delanaye, P., & Cavalier, E. (2024). Renal function assessment: Creatinine, cystatin C, and eGFR. Annals of Laboratory Medicine, 44(2), 135–143. https://doi.org/10.3343/alm.2023.0237

Shardlow, A., et al. (2017). Clinical utility and cost impact of cystatin C in CKD management. PLoS Medicine, 14(10), e1002400. https://doi.org/10.1371/journal.pmed.1002400

Zou, L. X., et al. (2020). Comparison of bias and accuracy using cystatin C and creatinine in CKD-EPI equations. European Journal of Internal Medicine, 80, 29–34. https://doi.org/10.1016/j.ejim.2020.04.044